Hyperbilirubinemia

Subscribe to Selected New Research on Hyperbilirubinemia

2030 relevant articles (63 outcomes, 154 trials/studies) found for this Disease

Description: A condition characterized by an abnormal increase of BILIRUBIN in the blood, which may result in JAUNDICE. Bilirubin, a breakdown product of HEME, is normally excreted in the BILE or further catabolized before excretion in the urine.

Also Known As:

Bilirubinemias; Hyperbilirubinemias; Bilirubinemia

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions

Pathologic Processes: 2210

Hyperbilirubinemia: 2030

Jaundice: 4782

Kernicterus: 344

Neonatal Hyperbilirubinemia: 320

Related Diseases

1.	Cholestasis
2.	Jaundice
3.	Kernicterus
4.	Liver Failure
5.	Birth Weight (Birth Weights)

Experts

1.	Newman, Thomas B: 3 articles (08/2008 - 02/2005)
2.	Kaplan, Michael: 3 articles (06/2005 - 10/2002)
3.	Drummond, G S: 3 articles (12/2001 - 07/2001)
4.	Kappas, A: 3 articles (12/2001 - 07/2001)
5.	Gökçay, E: 3 articles (10/2001 - 02/2000)
6.	Alpay, F: 3 articles (10/2001 - 02/2000)
7.	Sarici, S U: 3 articles (10/2001 - 02/2000)
8.	Huang, Ching-Shan: 2 articles (09/2008 - 11/2002)
9.	Huang, May-Jen: 2 articles (09/2008 - 11/2002)
10.	Escobar, Gabriel J: 2 articles (08/2008 - 02/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hyperbilirubinemia:

1.	BilirubinIBA 01/01/1999 - "CONCLUSION: A single dose of SnMP proved effective in controlling severe hyperbilirubinemia in full-term breastfed newborns with high bilirubin levels between 48 and 96 hours" 11/01/1992 - "The conclusion of our study is that the Wallaby System is useful in the treatment of neonatal nonhemolytic hyperbilirubinemia even if its effectiveness for higher bilirubin levels has still to be tested." 04/01/1996 - "Serial determinations of free bilirubin appear to be more helpful in the management of hyperbilirubinemia in infants with an increased risk of bilirubin toxicity." 07/01/2007 - "CONCLUSIONS: Our results suggest that the regime adopted is effective for detecting and preventing hyperbilirubinemia at risk of causing bilirubin-induced encephalopathy in term and near term newborn infants." 11/01/1990 - "We conclude that the determination of the HEF during biliary scintigraphy is helpful in distinguishing between intrahepatic and extrahepatic disease in patients with hyperbilirubinemia (bilirubin greater than or equal to 3.0 mg/dl)." Order ALL the reference details at left...
2.	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 07/01/1991 - "Ursodeoxycholic acid (600 mg/day) led to a prompt and sustained improvement in his hyperbilirubinemia" 11/01/2002 - "BACKGROUND: The purpose of this study was to evaluate the efficacy of ursodeoxycholic acid (UDCA) in the treatment of cholestasis and hyperbilirubinemia in a pediatric intensive care unit population" 03/01/1994 - "The aim of this study was to define factors predictive of the onset of the terminal phase, defined by hyperbilirubinemia or the occurrence of a severe clinical complication, in patients with primary biliary cirrhosis treated with ursodeoxycholic acid" 11/01/2002 - "RESULTS: Ursodeoxycholic acid was administered at a dose of 20 mg/kg per day to 5 PICU patients with cholestasis and hyperbilirubinemia of various etiologies" 11/01/2002 - "Ursodeoxycholic acid in the treatment of cholestasis and hyperbilirubinemia in pediatric intensive care unit patients." Order ALL the reference details at left...
3.	Phenobarbital (Luminal)FDA Link 04/01/2004 - "There was no significant reduction in incidence of hyperbilirubinemia in phenobarbitone group compared to in placebo group (6/37 (16.2%) versus 13/38 (34.3%); RR 0.47, 95% confidence interval: 0.20-1.11; risk difference: -18.1%, 95% confidence interval: -39.5 to 3.3%)" 04/01/2004 - "CONCLUSIONS: Prophylactic phenobarbitone is not helpful in reducing the incidence of hyper-bilirubinemia in "at risk" term neonates." 05/15/1975 - "Clinical experiences using phenobarbital in the prevention of hyperbilirubinemia in mature newborn infants in a controlled study]" 05/01/2001 - "For decades, phenobarbital (PB) treatment for hyperbilirubinemia has been known to increase expression of the UGT1A1 gene in liver" 07/01/1998 - "The hyperbilirubinemia seen in SM decreased in response to phenobarbital treatment, unlike that seen in CF" Order ALL the reference details at left...
4.	Clofibrate FDA LinkGeneric 11/01/1985 - "This study, added to the previous therapeutic trial performed in at term neonates, shows the efficacy of clofibrate in the preventive treatment of hyperbilirubinemia in preterm neonates" 11/01/1985 - "A double blind therapeutic trial of ethyl clofibrate as a preventive treatment of hyperbilirubinemia in preterm neonates was performed in neonates of gestational ages ranging between 31 and 36 weeks" 12/01/1981 - "Clofibrate for the treatment of hyperbilirubinemia in neonates born at term: a double blind controlled study (author's transl)]" 11/01/2007 - "CONCLUSION: A single dose of clofibrate (100 mg/Kg) along with phototherapy is more effective than phototherapy alone in treating non-hemolytic hyperbilirubinemia in term healthy newborn infants." 08/01/1995 - "BACKGROUND--Clofibrate (CFB) has been proposed to increase elimination of bilirubin in neonates with hyperbilirubinemia" Order ALL the reference details at left...
5.	EnzymesIBA 12/01/1992 - "The characteristics of her transient hepatic dysfunction were: early appearance (during the first day of life); discrepancy between the normal liver enzymes and high GGT concentrations; slow decrease of GGT, which nevertheless remained at above-normal concentrations even after the complete disappearance of direct hyperbilirubinemia; and spontaneous resolution in spite of only occasional breastfeeding" 07/01/2008 - "Direct hyperbilirubinemia and elevation of hepatic enzymes resolved in all but one patient by the time of discharge" 02/01/2008 - "The database was screened to find cases with unconjugated hyperbilirubinemia and normal liver enzymes and blood count values on simultaneous assays" 05/01/2007 - "A 7-year-old, spayed female, Wheaton terrier dog was icteric, lethargic, and anorexic with increased activity of hepatocellular and cholestatic liver enzymes and an extreme hyperbilirubinemia level of 609 micromol/L (reference interval: 1.0-4.0 micromol/L)" 07/01/2006 - "Finally, The hyperbilirubinemia was intra hepatic cholestatic in type due either to abnormality in permeability of hepatocyte or ductular membrane enzyme inhibition as the liver enzymes were not much elevated." Order ALL the reference details at left...
6.	Glucose (Dextrose)FDA LinkGeneric 05/01/1982 - "Refeeding the base-line diet reduced the hyperbilirubinemia by 66% in 12 hours, which was a significantly greater reduction than the effect of all other treatments except the largest dose of glucose given by intragastric route" 07/14/1995 - "Hyperbilirubinemia induced widespread decreases in LCMRglcs at P10 and had rather limited consequences on cerebral glucose utilization at P21" 03/01/1993 - "Hyperbilirubinemia occurred in 55% of babies in the glucose group compared with 21% and 22% in the saline and control groups, respectively (P < 0.001)" 05/01/1982 - "Effect of glucose administration on equine fasting hyperbilirubinemia." 07/01/2004 - "Neonatal hypoglycemia and hyperbilirubinemia was also encountered more often in babies of pregnant women with a positive 50-g glucose challenge test but negative 100-g glucose tolerance test" Order ALL the reference details at left...
7.	Heme (Haem)IBA 01/01/2006 - "Further studies are needed to fully elucidate the duration of this protection against hyperbilirubinemia due to a delayed heme load and any long-term consequences of prophylaxis with SnMP on HO-1 transcription and HO-1 protein." 07/01/2006 - "These data suggest that increased heme catabolism is an important mechanism responsible for hyperbilirubinemia in the first 4 days after birth." 10/01/1981 - "This demonstrates that a synthetic metalloporphyrin that is a potent competitive inhibitor of heme oxidation can, when administered to the newborn, also prevent the hyperbilirubinemia that normally develops postnatally" 10/01/1981 - "Sn-heme administration also entirely prevented the development of hyperbilirubinemia that normally occurs postnatally" 09/01/1980 - "Our data suggest that only LGA IDM are at increased risk for hyperbilirubinemia and that increased heme turnover is a significant factor in the pathogenesis." Order ALL the reference details at left...
8.	Carbon MonoxideIBA 08/01/2001 - "End-tidal carbon monoxide is predictive for neonatal non-hemolytic hyperbilirubinemia." 02/01/1999 - "CONCLUSIONS: The HcTX and the co-HcTX correct partially the hyperbilirubinemia of the Gunn rat" 01/01/1990 - "Pulmonary carbon monoxide (CO) excretion rates (VeCO) were 50% greater, on average, in Bolivian squirrel monkeys (BoSMs) which exhibit a unique fasting hyperbilirubinemia (FH), than in fasted control Brazilian squirrel monkeys (BrSMs)" 01/01/1990 - "Increased carbon monoxide excretion in Bolivian squirrel monkeys with fasting hyperbilirubinemia." 01/01/1981 - "Endogenous formation of carbon monoxide in Chinese newborn with hyperbilirubinemia." Order ALL the reference details at left...
9.	TransaminasesIBA 12/01/1990 - "Consequently, no hyperbilirubinemia and abnormal values of the serum transaminases were revealed in these neonates, and good results of nutritional supports were obtained by cyclic TPN" 01/01/2003 - "In HG virus monoinfection, biochemical studies revealed the enhanced activity of transaminases and hyperbilirubinemia that was absent in the mixed variant of HGV + HCV" 02/01/2007 - "Levels of liver transaminases slightly increased in four patients with FMF during the attack and two of these four patients had also mild hyperbilirubinemia" 08/01/2004 - "Markedly elevated aminotransferases, without hyperbilirubinemia, however, developed 7 and 9 weeks after the first and second donor lymphocyte infusion (DLI), respectively" 07/01/2001 - "Severe hyperbilirubinemia (23%) and elevated hepatic transaminases (18%) were usually transient" Order ALL the reference details at left...
10.	tin mesoporphyrinIBA 01/01/2006 - "The use of tin mesoporphyrin (SnMP) has been proposed for interdicting the development of severe hyperbilirubinemia in a variety of conditions" 07/01/2005 - "CONCLUSION: The possible strategies for implementing an approach to the management of hyperbilirubinemia (especially the haemolytic kind) in the presence of BBS may include an exchange transfusion carried out at lower TSB concentration than previously recommended or an early administration of Sn-mesoporphyrin." 09/01/2003 - "Tin-mesoporphyrin in the treatment of severe hyperbilirubinemia in a very-low-birth-weight infant." 10/01/2002 - "In a near future enzymatic inhibitors such as Sn-mesoporphyrin will be probably available for the treatment of severe hyperbilirubinemia." 12/01/2001 - "Treatment of hyperbilirubinemia pharmacologic approach SnMP(tin-mesoporphyrin)." Order ALL the reference details at left...

Therapies and Procedures

1.	Phototherapy (Light Therapy) 05/01/2007 - "CONCLUSIONS: Our results demonstrate that the efficacy of Super LED phototherapy for treating hyperbilirubinemia in premature infants was significantly better than halogen phototherapy." 02/01/2000 - "The efficacy of double phototherapy, in the form of conventional phototherapy with special blue light plus fiberoptic phototherapy, was compared with conventional phototherapy consisting of special blue lamps alone in a relatively larger series of term newborns with significant hyperbilirubinemia" 02/01/1992 - "The latencies of peak V and interpeaks I-V and III-V in the brain-stem auditory evoked response of infants with hyperbilirubinemia before phototherapy were significantly greater than those in a control group of infants" 02/01/1991 - "These findings suggest that high-dose IVGG may be useful in the treatment of hyperbilirubinemia due to isoimmune haemolytic disease resistant to phototherapy." 11/01/1998 - "We conclude that light from LEDs should be considered a more effective treatment for hyperbilirubinemia than light from presently used phototherapy devices" Order ALL the reference details at left...
2.	Liver Transplantation 12/01/1990 - "During clinical follow-up the recurrence or persistence of hyperbilirubinemia along with deteriorating results of coagulation studies indicated the need for liver transplantation because of imminent poor outcome" 02/01/2008 - "CONCLUSION: Hyperbilirubinemia is a common clinical manifestation after liver transplantation with multiple and complicated causes" 02/01/2008 - "OBJECTIVE: To investigate the causes and treatment of postoperative hyperbilirubinemia after orthotopic liver transplantation" 02/01/2008 - "The etiology and management of postoperative hyperbilirubinemia after orthotopic liver transplantation]" 11/01/2006 - "CONCLUSIONS: It suggests that hyperbilirubinemia is the only risk factor for BT, and BT is associated with an increased infectious rate after liver transplantation." Order ALL the reference details at left...
3.	Plasma Exchange 11/01/1986 - "Our clinical data suggested that plasma exchange using Evaflux-2A and an albumin-added electrolyte solution as the substitute fluid was useful in the treatment of hyperbilirubinemia." 01/01/1991 - "This study was undertaken to assort the group of posthepatectomy hyperbilirubinemia by occurring time for helping elucidate its indication of plasma exchange (PE)" 03/01/2002 - "The beneficial effects of plasma exchange could be attributed to amelioration of the toxic effects of hyperbilirubinemia on hepatocyte and renal tubular cell function" 03/01/2002 - "Plasma exchange was instituted in view of the severe hyperbilirubinemia (970 micromol/liter)" 06/01/2000 - "Plasma exchange for hyperbilirubinemia following implantation of a left ventricle assist system: a case report." Order ALL the reference details at left...
4.	Transplants (Transplant) 03/01/2005 - "No cases showed posttransplanted hyperbilirubinemia above 10 mg/dL in group N; however, all cases were small-for-size grafts" 12/01/2004 - "Results of a multivariable model showed that treatment was prolonged in patients who received peripheral blood cells, in male patients with female donors, in those with graft-versus-host HLA mismatching, and in those with hyperbilirubinemia or multiple sites affected by chronic GHVD at the onset of the disease" 11/01/2002 - "Preoperative three-dimensional computed tomography (3D-CT) of the donor revealed a small right hepatic vein (RHV) without inferior RHV and a large middle hepatic vein (MHV) draining segments 5 and 8. During the donor operation, right lobe graft was harvested with the MHV, preserving the drainage vein from segment 4. The donor recovered uneventfully except for mild transient hyperbilirubinemia" 04/01/2001 - "Hyper-bilirubinemia and elongation of prothrombin time persisted longer in the small graft group than in the large group (p < 0.0001 for both)" 01/01/1995 - "CONCLUSION: Transplants of small intestine with known UDPGT activity partially corrected the deficiency in Gunn rats and allayed the hyperbilirubinemia" Order ALL the reference details at left...
5.	Enteral Nutrition (Feeding, Tube) 06/01/2005 - "CONCLUSION: These data demonstrate for the first time that although PN-dependent infants can achieve normalization of marked hyperbilirubinemia with enteral nutrition, the improvement in liver function usually begins only after full enteral nutrition is tolerated and PN is withdrawn" 06/01/2005 - "The aim of this study was to assess whether increasing provisions of enteral nutrition can improve PN-associated hyperbilirubinemia over time" 08/01/2003 - "From day 150 on the patient was treated with low doses of enteral nutrition into the segment of intestine between the fistulas, in connection with the subsequent decrease of two-month lasting hyperbilirubinemia of 200-260 mumol/l" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Hyperbilirubinemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 63 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>